TWI242436B - Therapeutically acceptable glucocorticosteroid in the form of a powder which is steriole according to the us pharmacopoeia 23/NF18, sterile pharmaceutical formulation comprising the same, and process for the sterilization of a glucocorticosteroid - Google Patents
Therapeutically acceptable glucocorticosteroid in the form of a powder which is steriole according to the us pharmacopoeia 23/NF18, sterile pharmaceutical formulation comprising the same, and process for the sterilization of a glucocorticosteroid Download PDFInfo
- Publication number
- TWI242436B TWI242436B TW087118179A TW87118179A TWI242436B TW I242436 B TWI242436 B TW I242436B TW 087118179 A TW087118179 A TW 087118179A TW 87118179 A TW87118179 A TW 87118179A TW I242436 B TWI242436 B TW I242436B
- Authority
- TW
- Taiwan
- Prior art keywords
- glucocorticosteroid
- patent application
- scope
- item
- less
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000003862 glucocorticoid Substances 0.000 title claims abstract description 62
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 title claims abstract description 11
- 238000004659 sterilization and disinfection Methods 0.000 title abstract description 21
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 24
- 229960004436 budesonide Drugs 0.000 claims abstract description 22
- 239000002245 particle Substances 0.000 claims abstract description 19
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims abstract description 11
- 229950004432 rofleponide Drugs 0.000 claims abstract description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims abstract description 9
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims abstract description 6
- 229950000210 beclometasone dipropionate Drugs 0.000 claims abstract description 6
- 229960000289 fluticasone propionate Drugs 0.000 claims abstract description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims abstract description 5
- 229960002744 mometasone furoate Drugs 0.000 claims abstract 4
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims abstract 4
- 238000010438 heat treatment Methods 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 21
- 150000003431 steroids Chemical class 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000010419 fine particle Substances 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000015170 shellfish Nutrition 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229930182558 Sterol Natural products 0.000 claims 3
- 150000003432 sterols Chemical class 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 24
- 238000009472 formulation Methods 0.000 description 21
- 239000000523 sample Substances 0.000 description 17
- -1 fiunisOHde Chemical compound 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 6
- 235000013539 calcium stearate Nutrition 0.000 description 6
- 239000008116 calcium stearate Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 4
- 229940092705 beclomethasone Drugs 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 238000004380 ashing Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000001761 ethyl methyl cellulose Substances 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940072266 pulmicort Drugs 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 101100279436 Caenorhabditis elegans egg-2 gene Proteins 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 101000643395 Escherichia phage T7 Single-stranded DNA-binding protein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003840 cortivazol Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
1242436 玖、發明說明: 本發明係關於一種呈粉末型式之糖皮質類固醇,無菌糖皮 質類固醇’含糖皮質類固醇之無菌調配物之滅菌法及其在治 療鼻或肺之過敏及/或發炎病症之用途。 發明背景 過去已經建議各種使糖皮質類固醇滅菌之方法。 PT-A-69652揭示使用環氧乙烷與二氧化碳進行之微粉化糖 皮質類固醇低溫滅菌法,因為,根據pT_A_69652,呈粉末型 式之顯固醇於60 C以上之溫度並不安定。糖皮質類固醇之特 疋貝例為晋烈得納西g同(prednacind〇ne),地塞米松 (dexamethasone)與脫氫皮質脂醇,及其鹽,酯與氟基衍生物, 其包括地塞米松醋酸酯,地塞米松磷酸酯,三甲基醋酸去氫 皮質酯醇及9- α氟基去氫皮質脂醇。然而,環氧乙烷具毒性, 且當被使用以使糖皮質類固醇滅菌時,頃發現環氧乙烷之殘 留量與需要非常低殘留量環氧乙烷之藥學原理相違背。因 此,頃發現此種方法不適於產生治療上可接受之糖皮質類固 醇及其調配物。 美國專利US-A-3962430揭示一種製造無菌藥劑之等張溶 劑之方法,其包括於lOOt下添加該藥劑至氯化鈉之飽 溶液中,然後於100-130°C下使該混合物加熱。此種孟 不適於作為吸入用之糖皮質類固醇之微細粒子 』心/予液,因此 其含有水,且此種方法包括加熱與冷卻,會使粒子大 不好的變化。的確,其可導致微細粒子之間
間形成橋,因此J 生大、硬聚集體,當用藥時不能解聚成所要微細粒子
〇:\55\55669-921222. DOC 1242436 勺曰代法為乾熱滅菌法。根據歐洲藥典(1996,第 83 284頁)般熱滅菌法係於180°C下進行30分鐘或於最 低16 0 °C下進行$小9 ϊ。士 丁主夕2小日守。根據北歐藥典(i 964,第1 6頁), 此種滅菌法可以於14(rc下進行3小時。然而,於這些方法 之μ度下糖皮貝類固醇會遭受明顯解降,且容易在其表面 結構上產生變化。 、工由/3或r -I射之滅菌法亦為人所知。的確,依蘭(111賊) 與莫勒(M〇eller)在 Arch. pharm chemi %,第 2 版,1974 年第167_ 174頁中建議使用此種輻射法以使糖皮質類固醇 滅菌 '然@ ’當使用此種輻射法使某些微細緻(例如,微粉化) 糖皮質類固醇滅菌時,糖皮質類固醇會明顯解降。 頒予Andaris公司之WO_A_96/〇9814係關於具有質量中位 粒子大小為1 1 H)微米之水溶性物質之噴霧乾燥粒子。該發 明之目標係產生供使用於乾燥粉末吸入器之均勻且可再製之 粒子。該水溶性物質較佳為呈天然或重組型式之人體蛋2質 或其碎片’例如人體血清(腸)…抗胰蛋白酵素或醇脫氯 酶。亦製成具有載體之活性物質之組合物,例如,布德索耐 德(budesonide)及乳糖。一般認為所製成之該微粒子可以不含 細菌’而不必講述是如何達成無菌,也不必顯示任何證據。3 頒予Astra AB之W〇-A-96/32〇95係關於—種製備可呼吸粒 子之方法,其包括使吸劑化合物溶解在溶劑中, …T,將壬小滴型 式或如噴射蒸汽之含有該吸劑化合物之所形成溶液導入^ 溶劑中,其可以與溶劑混溶,並且經攪動 見軔使用本方法製成 具有質量中位直徑(MMD)低於1〇微半夕士 + 士文木之布德索耐德
O:\55\55669-92I222.DOC 1242436 (Budesonide)。在W〇_A_96/32〇95中並沒有關於滅菌法或無 菌粒子之資料。 頒予 Instytut Farmaceutyczny 之 WO-A-92/11280 係關於一 種獲得布德索耐德之(22R)非鏡像立體異構物之方法,其包括 進饤縮合反應,接著使自乙醇進行縮合反應之粗產物結晶 化。使所獲得之布德索耐德(22R)之2卜醋酸酯水解,然後使 口此獲得之產物自醋酸乙酯結晶化。該布德索对德之(22S) 非鏡像立體異構物含量為或較低。在WQ-A-92/11280中 並/又有關於滅菌法或無菌粒子之資料。 我們亦已發現該醫藥調配物(尤其是糖皮質類固醇之懸浮 液’例如水性懸浮液)之末期滅菌法之嚐試已全部證明無法令 人滿意。由於糖皮質類固醇之大部份粒子會在濾器上,所以 此種懸浮液通常不能使用無菌過濾殺菌。我們亦顯示濕熱滅 菌法(例如,含有該產物之玻璃管瓶進行之蒸汽處理)會使粒 子大小產生令人無法接受之改變。 各種微細敏糖皮質類固醇之水性懸浮液廣為人知,例如, 稱為Pulmicort®霧化懸浮液之含布德索耐德之產物。 (Pulmicort® 是瑞典 Astra AB 之商標)。自 WO_a_95/31964 得知類似之氟替卡松(fluticasone)丙酸酯調配物。 因此,需要一種使糖皮質類固醇(與含該物質之調配物)滅 菌之新穎方法。 々人馬e牙的疋’我們目别頃發現可以於比其它物質之熱滅 菌法所需之溫度還更明顯低之溫度下進行乾糖皮質類固醇之 有效滅菌。可以使用此種無菌糖皮質類固醇以製備含無菌糖 O:\55\55669-921222.DOC -10 - 1242436 皮質類固醇之無菌調配物。 發明說明 根據本毛明,係提供一種使糖皮質類固醇滅菌之方法,此 〆;100至130 c溫度下,熱處理該呈粉末型式之糖 皮質類固醇。本方法較佳於110 i 120t:溫度(更佳於約no C )下進行車乂佳費時至高約24小時,更佳至高i 〇小時,例 如尸自1至10小時。本方法較佳於惰性氣體大氣(例如,氬 或氮大氣)下進行。 =人驚訝的是,我們頃發現當應用此種方法至該糖皮質類 口醇布彳^、索耐德¥ ’比當應用至比較物質硬脂酸鈣可殺死更 多孢子。 咸信(但我們並無意受本解釋文限制)可以使該糖皮質類固 醇滅菌(對照硬脂酸鈣)之意外低溫顯示當與熱處理一起併用 時’在摧毀孢子之功用上,該糖皮質類固醇可提供協同效果。 本發明使用之糖皮質類固醇較佳為例如,供使用於鼻與口 吸藥之抗發炎糖皮質類固醇。可以使用本發明中之適合糖皮 質類固醇實例包括万米松,氟替卡松(例如,呈丙酸酯型式), 布德索耐德,替布雷登(tipredane),地塞米松,貝克羅米松 (beclomethasone,例如,呈二丙酸酯型式),去氫皮質脂醇, 氟西諾龍(fluocinolone),氟羥脫皮質脂醇(例如,呈丙_化物 型式)’莫米松(momethasone,例如,呈糠酸酯型式),羅飛 波耐德(rofleponide,例如,呈棕櫚酸酯型式),氟米松 (flumethasone),氟尼索利德(fiunis〇Hde),西克雷索耐揀 (ciclesonide),去夫拉扎可特(deflazac〇rt),可替巴坐 O:\55\55669-921222.DOC -11 - 1242436 (cortivazol), 16α,17α-亞丁基二氧基_6 4-二羥基·脈-ΐ,4-二烯-3,20-二酮; 說基-娠-1,4-二烯-3,20-二酮;6α α,9 α -二氟-11 /3 ,9〇;-二氟-11 /5 ; 21-二 ,9α _二氟-11冷-羥基_16 α,丨7 α -亞丁基二氧-甲基硫代·雄脂 -4-烯-3_酮;S-曱基,16 «,17α _亞丁基-二氧·6α,9κ氟七万_羥基冬酮基,脂 一1斗二烯170-敌硫代酸酯;甲基9α •氣基 經基七α-甲基-3,基-17α__基氧_雄脂义4_二稀_17心 她:;^心-二氣七^羥基七心甲基韻基-…-丙 I基氧-雄脂-1,4-二烯-ΐ7/5 _羧硫代酸1(2_酮基-四氫呋喃 基)S曰,視而要壬其純異構型式(其中存在此種型式)及/或 /、酉曰纟但醛或鹽型式。較佳使用布德索耐德,羅飛波耐德, 維飛波耐德棕櫚酸酯,莫米松糖酸酯,貝克羅米松二丙酸酯 或氟西諾施丙酸酯,更佳使用布德索耐德,羅飛波耐德或羅 能波耐德棕櫚酸酯,且最佳使用布德索耐德。 孩皮貝類固醇較佳呈微細緻(例如,微粉化)粉末型式使 用,尤其呈具有質量中位直徑低於1〇微米(更佳,低於5微 米)之U細緻粒子型式使用。或者,該糖皮質類固醇可以呈超 、、田、、致型式,例如具有質量中位直徑低於i 〇微米。可以經由 本質上係已知之習用技術(例如,利用微粉化或直接沉澱)製 成U、、、田緻粒子。關於微粉化之資料可以在例如,美國,費城, Lea & Febiger,1976 年,第 2 版,Lachman,Lieberm讓及 g 之 The Theory and Practice of Industrial Pharmacy,,中 找到。 所使用滅菌器之溫度,時間,分批大小及種類係相互依賴。
O:\55\55669-921222.DOC -12- 1242436 因此,根據本發明之方法,通常,所使用之溫度愈高,使糖 皮質類固醇滅菌所需時間愈少。較佳以不超過8小時(例如, 1至8小時)進行本方法,當溫度高於約110°c時,更佳不超 過4小時。於約i2〇t:溫度下;較佳以不超過4小時(例如, 1至4小時)’更佳不超過2小時(例如1至2小時)進行本方 法。 於約110 c至高130°C溫度下,一批50克糖皮質類固醇可 適合經熱處理1至4小時。若有需要,則可使用次批,例如, 4x50 克。 可以進行本方法以致使抗熱孢子之數量減少超過4對數。 適θ進行本發明之方法以致使抗熱抱子之數量減少6對數。 車父佳進行本發明之方法以致使抗熱孢子數量減少超過6對 數,更佳超過7對數。 一種記述滅菌法效力之不同方法為使用D值。該D值(亦 稱為Dt值)為於特定溫度T ( C )下,減少孢子標準群體9〇〇/。 或1對數週期(亦即1/1〇之殘存部份)所需之時間(以分鐘表 示)。 可以進行本方法以致使於預定溫度T下,該d值低於約24〇 分鐘,其中丁在100至13(TC範圍内。適合進行本發明之方 法以致使於預定溫度T下,該D值低於150分鐘。較佳進行 本發明之方法以致使於預定溫度T下,該d值低於90分鐘, 更佳為致使於預定溫度T下,該D值低於30分鐘。τ較佳 為 100,110,120 或 13CTC。 較佳以大部份該糖皮質類固醇可達成所要時間之所要溫 〇:\55\55669-921222.DOC -13- 1242436 度,並維持在其間之方式進行該滅菌法。 可以分批或連續(以分批較佳)進行本方法。 本方法使用之糖皮質類固醇 鉍刑彳、4人〜# 子、始物貝(该物質可以呈微細 古、^ 土 方即3有低於約1% (w/w)水。本 方法之起始物質較佳含有低 〇.3%(,水。 …G.5/° (叫水,且更佳低於 本方法之糖皮質類固醇起始物質之生物 CFU(菌落形成單位)。本 ^ — 炙月之搪皮貝類固醇起始物質之為 母克低於1GCFU ’更佳為每克低於1CFU。 根據本發明係進一步提供一 j如貝里中位直徑低於1 0 欲米,且更佳低於5微米之盔鈷棘+併』 …囷搪皮貝類固醇[例如,布德索 耐德(budesonide)],盆輕伟;^人卜 、,。 刈,、?乂仫不含水,並呈微細緻粒子型式。 該名詞”無菌”係意指可符合根據美㈣典23/刪8, 1995 年’第 1686_1690 頁盥 1963-1 Q7s w I ^, 只” i%3-1975頁中所描述之無菌標準之 產物i其提供-種治療上可接受之糖皮質類輯及其調配 物。有關最終產物無菌之其它規定包括歐洲藥典(ph·恤. 1998 ’ 2.6.1 與 5.1.1 章),英國藥典(Bp 1993,附錄 χνι a p A18〇與附錄XVIII A,p. A184)及日本藥典(jp,第i3版,’第 69:71頁肖181_182頁)。該治療上可接受之糖皮質類固醇及 其D周配物較佳由可提供根據美國藥典23/Nm 1年,第 1686-169G頁與1963_1975頁之無菌保證之方法製成。 根據本發明之糖皮質類固醇本質上可維持與經本發明方法 製成之起始物質相同之藥理活性與物理_化學性質/其化學純 度與物理型式,亦即,由本發明滅菌法引起之降解(尤其,化 O:\55\55669-921222.DOC -14- 1242436 學降解)受到限制。 根據本發明之糖皮質類固醇較佳至少98.5重量%純,更佳 至少99重量%純,且最佳至少99·2重量%純。 本發明進一步提供一種供使用以治療鼻或肺之過敏及/發 炎病症(例如,慢性阻塞性肺病(c〇PD),鼻炎或氣喘)之無菌 糖皮質類固醇,較佳抗發炎糖皮質類固醇,更佳布德索耐德 (budeSonide),羅飛波耐德(r〇flep〇nide)或羅飛波耐德棕櫚酸 酯,最佳布德索耐德。本發明提供使用此種無菌糖皮質類固 醇(較佳,抗發炎糖皮質類固醇,更佳布德索耐德)以製造治 療此種病症之藥物(較佳,無菌藥物)。 根據本發明係進一步提供一種包含糖皮質類固醇之水性製 淨液之無菌醫藥調配物,其中該糖皮質類固醇較佳為無菌微 細緻糖皮質類固醇,例如,布德索耐德。 根據本發明亦係提供一種無菌醫藥調配物,其包含糖皮質 頟固醇與或多種醫樂上可接受之添加物、稀釋劑或載劑。 此種添加物之實例包括表面活化劑,pH調整劑,螯合劑,懸 浮液等參劑及增稠劑。 為了使該糖皮質類固醇粒子有效分散在懸浮液中,可以使 用表面活化劑,且視需要與例如,卵填脂組合使用。在根據 本發明之调配物中,該表面活化劑亦可作為安定劑。適合之 表面活化劑實例包括烧基芳基聚醚醇型之非離子表面活化 劑,明確地說,係Τγ1〇χ^〇;μΤΜ具有環氧乙烷與曱醛之 4-(1,1,3,3,-四甲基丁基)酚聚合物。其它適合之表面活化劑包 括山梨糖醇酐衍生物,例如,聚氧化乙烯山梨糖醇酐脂肪酸
O:\55\55669-921222.DOC -15- 1242436 酉曰較佳為聚山梨酸酯(p〇iys〇rbate)或TweenTM群,更佳為 聚山梨酸酯80或聚氧化乙烯20山梨糖醇酐單油酸酯 CTweenTM 80),適合之表面活化劑亦包括聚氧化乙烯醇,尤 其聚氧化乙烯烷基醚,較佳為五乙二醇單正-十二烷基醚或 Ci2E5 ’其它適合之表面活化劑包括巴露索莫(poioxamers), 聚氧化乙烯蓖麻油衍生物,聚乙烯醇與聚氧化乙烯,聚氧化 丙稀’聚氧化丁烯及聚乙二醇(PEGs)之嵌段共聚物或任何這 些之混合物。其它適合之表面活化劑包括聚乙二醇衍生物, 尤其聚乙二醇660羥基硬脂酸酯或s〇lutolTM HS 15,波比酮 (povidone),聚乙烯基吡咯酮(pvp)及聚乙二醇(pEGs)。 该表面活化劑可佔該調配物重量之約0.002至2%。該聚氧 化乙稀山梨糖醇酐脂肪酸酯較佳佔該調配物之約〇.〇〇5至 〇·5% ’巴露索莫(p〇i〇xamers)佔約〇·〇ι至2%,而聚氧化乙烯 烧基驗或聚氧化乙烯蓖麻油衍生物佔約0.01至1.0%。 若需要可調整該懸浮液之pH。適合之pH調整劑實例為弱 有機酸(例如,檸檬酸),強無機酸(例如,鹽酸),及強鹼藥劑 (例如’ NaOH)。或者,經由平衡緩衝劑之酸與鹽型(例如, 挣杈酸,檸檬酸鈉,醋酸,醋酸鈉及磷酸鈉)可以調整該系統 之pH。作為吸劑用之調配物較佳具有pH在約3.5至約6 〇 範圍内’更佳為4·0至5.0,最佳為4.2至4.8。 該調配物較佳含有適合之螯合劑,例如,乙二酸四醋酸二 鈉。該螯合劑佔該調配物重量之約〇 〇〇5至〇1〇/〇。 可以添加懸浮液等滲劑。其實例為右旋糖,甘油,甘露醇, 氯化鈉,氣化鉀及溴化鈉。 O:\55\55669-921222.DOC -16- 1242436 為了形成不太可能凝聚或形成沉積物之技懸浮液,可以 將增稠劑包括在本調配物中。摘人+ r 適合之增稠劑實例為纖維 生物’較佳為纖維素_,或微晶性纖維素。較佳之纖维素_ 包括乙基纖維素,乙基甲基纖維素,經乙基纖維素,經乙基 甲基纖維素,羥乙基乙基纖維素, " 素,經丙基纖維素,經丙基U纖維 内丞f基纖維素及羧甲基纖維辛 (置),例如,其納鹽。適合之增稠劑亦包括環糊精及糊精^ 適合之增稠劑尚包括黃酸樹膠,瓜耳樹膠及卡波莫 (Carb〇麟)。本發明調配物之較佳增稠劑為波比酮 (P〇vid_),聚乙烯基料輞(pvp)及聚乙二醇(pEGs)。 該增稠劑佔該調配物重量之約至30%。較佳為微晶性 纖維素與竣甲基纖維素(CMC)鈉佔約05至2.5%,黃酸樹膠 佔約〇.3至3%,卡波莫(carb〇mer)佔約〇1至2%,瓜耳樹膠 佔約0.3至2%,而羥丙基甲基纖維素佔約〇·5至3〇%。 在該懸浮液中,活性組份(例如,布德索耐德)係以小粒子 至式存在’其甲至少9〇〇/0小粒子之質量中位直徑(MMD)低於 20微米,較佳至少8〇%低於1〇微米,更佳至少7〇%低於7 微米,且最佳至少6〇%低於4微米。 該懸浮液較佳含有約〇·〇5至約2〇毫克/毫升糖皮質類固 醇。該懸浮液更佳含有約〇·〇8至1〇毫克/毫升糖皮質類固 醇,且最佳含有〇·1至5毫克/毫升糖皮質類固醇。 根據本發明方法滅菌之無菌醫藥調配物(其包含糖皮質類 固醇’例如’微細緻布德索耐德(budes〇nide),羅飛波耐德 (fofleponide)或羅飛波耐德棕櫚酸酯)之製法為使已滅菌之糖
O:\55\55669-921222.DOC -17- 1242436 皮質類固醇與任—種適合之額外成份(例如,表面活化劑 周正Μ或螯合劑’懸浮液等滲劑或增稠劑)混合。除了今糖 質類固醇外’全部組份可以經由其水溶液之無®過濾;成。 了:於無囷且惰性氣體(例如,氮或氬)之過壓下貯藏所形成 =囷懸子液,然後應該於無菌條件下,使用,例如,吹/填/ 3系統,將其裝人已預先殺g之容器内以產生—種 樂產物。 — 本發明進一步提供—種治療鼻或肺發炎病症之方法,盆包 ㈣罹患此種病症之哺乳動物(尤其,人類)投予治療上有效 量之無菌糖皮質類固醇或含有糖皮f類固醇之無菌調配物, 較佳為含有根據本發明製成之無菌糖皮質類固醇之無菌調配 物。更準確地說,本發明係提供一種治療慢性阻塞性肺病 (COPD) ’鼻炎’氣喘或其它過敏及/或發炎病症之方法,其 包括對罹患此種病症之哺乳動物(尤其,人類)投予治療上有 政里之無困糖皮質類固醇或含有糖皮質類固醇之無菌調配 物’較佳含有根據本發明製成之無菌糖皮質類固醇之無菌調 配物。 實例 芩考以下貫例(其並無意限制本發明)說明本發明。 實例1 進行實驗以測定熱處理對微灰化布德索耐德(budesonide) 5式樣之化學純度及物理型式之影塑。 如表1所不,使9批各5〇克之微灰化布德索耐德(下表i 中试樣號數二-:^丨在乾滅菌器^^匕⑶型^^^^⑴中進行熱處
O:\55\55669-921222.DOC -18- 1242436 理。試樣1並未進行此種處理,因此使用來作為參考試樣。 熱處理後’分析各試樣之化學與物理性質。 表1 號數 1 2 3 4 5 6 7 8 9 10 溫度/°c - 100 100 100 110 110 110 120 120 120 時間/小時 0 4 6 10 2 4 10 1 2 4 大小/微米 2.0 2.2 2.2 2.2 2.2 2.2 2.3 2.2 2.2 . 2.3 大小範圍(10-90%)/微米 2.6 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 蛋白立體異構 物A/重量% 48.8 48.8 48.7 48.7 48.7 48.8 48.7 48.7 48.7 48.7 布德索耐德 (Budesonide) 含量1重量% 99.4 99.3 99.3 99.2 99.2 99.3 98.9 99.2 99.2 99.0 已知外來類固 醇之總數 0.13 0.14 0.16 0.15 0.16 0.15 0.18 0.14 0.15 0.17 未知外來類固 醇之總數 0.04 0.04 0.05 0.05 0.04 0.08 0.18 0.04 0.07 0.16 O:\55\55669-921222.DOC -19- 1242436 熱處理後,與試樣1比較,各試樣之布德索耐德(budesonide) 之布魯諾耳-埃梅特-泰勒(Brunauer,Emett and Teller)(BET) 表面值(使用Micrometries Gemini 2375儀器測定;亦見英國 標(British Standand) 43 59 (1969)第一部)或其 X-射線繞射圖 案並沒有改變。使用Coulter計數器測定各試樣之質量中位 直徑(MMD)之大小。 實例2 比較布德索耐德與硬脂酸鈣之滅菌法。 0·5克布德索耐德與〇.5克硬脂酸鈣試樣各經含有1.5xl07 孢子之 0.1 毫升 Steris Bacillus subtilis (globigii)(批號 LG126B)孢子懸浮液接種。使用與實例i相同之技術與裝置, 於110。(:溫度下使各試樣進行反應。測定各試樣之孢子群 體,所獲得之結果顯示在下表2中。 表2 化合物 前 後 硬脂酸鈣 1.5X107 孢子 3.3 X 1〇6 抱子 布德索耐德(Budesonide) 1.5X107 孢子 <10孢子 由於熱處理之結果,在該已接種之布德索耐德試樣中,孢 子對數減^大於6 · 2,然而,在已接種之硬脂酸鈣試樣中,對 數減少低於0.7。 實例3 包合經由實例2之方法滅菌,且符合美國藥典23/NF18,
O:\55\55669-921222.DOC -20- 1242436 1 9 9 5之無菌標準之微細緻布德索财德之調配物之製法為混 合以下成份: 表3 微灰化布德索耐德(budesonide) 0.125毫克 乙二胺四乙酸二鈉 0.1亳克 氯化鈉 8.5毫克 聚山梨酸酯80 0.2毫克 無水檸檬酸 0.28毫克 檸檬酸納 0.5毫克 純水、 至1毫克 除了布德索耐德外,全部組份經由其水溶液之無菌過濾製 成,然後於無菌條件下,將適量所形成懸浮液(約2毫升)裝 入已預先殺菌之5毫升容器内以產生一種無菌產物。 可以於無菌氮氣之過壓下貯藏所形成懸浮液,然後使用吹/ 填/密封系統將其裝入容器内。 實例4 包含經由實例2之方法滅菌之微細緻布德索耐德之無菌調 配物可經由混合以下成份而製成: O:\55\55669-921222.DOC -21 - 1242436 表4 微灰化布德索对德(budesonide) 2-3毫克 乙二胺四乙酸二鈉 0.1毫克 氯化鈉 8.5毫克 安定劑 0.02-2毫克 無水檸檬酸 〇·28毫克 檸檬酸鈉 0.5毫克 純水 至1毫升 除了布德索耐德外,全部組份可經由其水溶液之無菌過淚 製成,然後於無菌條件下,將適量所形成懸浮液(約2毫升) 裝入已預先殺菌之5毫升容器内以產生一種無菌產物。 可以於無菌氮氣之過壓下貯藏所形成懸浮液,後後使用吹/ 填/密封系統將其裝入容器内。 實例5 5克微灰化布德索耐德經約2毫彳Bacmus _偷之抱子 懸浮液接種。 然後於551下乾燥約 德與20-40克未經接種 3小 之微 使該物質與孢子懸浮液混合, 時。使已接種並乾燥之布德索耐 灰化布德索耐德混合。 此 兄不斌樣經熱處理 下,經不同加熱時間後取出i克試樣。將
O:\55\55669-92I222.DOC -22- 1242436 1克之試樣轉移至10毫升稀釋培養基(pH 7 2)中。以〇1%腺 水洛液製成合適之稀釋液’並且根據美國藥典23/NF丨8, 1995,第1681_1686頁(尤其,1684頁)之傾注盤技術測定孢 子/克數。 測定已於80°C下加熱10分鐘以殺死有生長力的細胞之試 樣中,熱處理前之抱子數。 結果顯示表5中,其中該DT值為於T溫度(。〇下,熱處理 前及後,使孢子數減少1對數所需之時間(分鐘)。 表5 80°C 於100°c下加熱時間 10分鐘 15分鐘 45分鐘 75分鐘 抱子/克 6.5 X106 4.8 X103 7.1 Χ102 1.7 Χ102 對數孢子/克 6.81 3.68 2.85 2.23 1^100=41.5 分鐘,相關係數=-〇·〇996 此意指於100°C溫度下,需要6x41.5分鐘才能使孢子數減 少6對數。 於110°C下加熱 80°C 於: ____— I10°c下加熱時間 10分鐘 5分减 ..^ 15分鐘 20分鐘 孢子/克 2X106 2.08〆 1〇4 ^^— 9.25 X102 3.55X102 對數孢子/克 6.20 4.32 ^— 2.97 2.55 O:\55\55669-921222.DOC -23- 1242436 D!!〇=8.3分鐘;相關係數0.995 能使孢子數減少 此意指於ll〇°C溫度下,需要6χ8·3分鐘才 6對數。 表5(續) 於120°C下加熱 80°C 於120。(:下加熱時間 10分鐘 4分鐘 6分鐘 8分鐘 孢子/克 1.5 X106 1.9X102 5.5X101 2X101 對數孢子/克 6.19 2.28 1.74 1.30 〇12〇=4.1分鐘;相關係數=-〇.998 此意指於120°C溫度下,需要6x4.1分鐘才能使孢子數減少 6對數。 以類似貫例5使用之方法,使1克微灰化布德索耐德,脫 氫皮質脂醇及貝克維米松(beclomethasone)與0.5克羅飛波耐 德(rofleponide)經不同孢子懸液液接種。 於110T:下使各試樣經熱處理。經各種加熱時間後取出一 種試樣。經由根據美國藥典23/NF18,1995,第1681-1686 頁(尤其’第1684頁)中之注入盤技術測定每克之孢子數。 自熱處理前與後之孢子數計算孢子之對數減少與十進位的 減少時間(於特定溫度下,減少丨對數之微生物數所需時間)。 結果顯示在表6中。
O:\55\55669-921222.DOC -24- 1242436 表6 於110°c下加熱 糖皮質類固醇 以分鐘表示之d11q 布德索财德(Budesonide) 41 羅飛波耐德(Rofleponide) 9.8 貝克羅米松(Beclomethasone) 72.7 〜 脫氫皮質脂醇 73.8 —^ 表6清楚顯示本方法能夠很有效的減少含有糖皮質類固醇 之4樣中之孢子數。本方法尤其對布德索耐德與羅飛波耐德 有效。事實上,在全部丨.〇克羅飛波耐德試樣上進行之分析 可以以很短之循環時間(於110°C下,-5分鐘)產生總致死, 其中D110值無法計算。 比較實例7 輻射 使貯藏在塑膠容器中之約3克微灰化布德索耐德物質接受 幸田射。使該物質曝露至2·5至25千瑞(kGy)之/5 -輻射,及8 至32千柘之7 •輻射。曝露後,經由液相層析法測定該布德 索耐德含量及相關物質之含量。布德索耐德之化學安定性被 認為是研究結果之最重要參數。
O:\55\55669-921222.DOC -25- 1242436 表7 在輻射滅菌時,微灰化布德索耐德(budesonide)物質之安定性 曝露密度 (千瑞kGy) 參考1) β 2.5 β 5 β 10 β 17 β 25 r 7.8 r 31.9 布德索耐德 (budesonide)含量 % 99.5-99.8 99.1 98.9 98‘9 98.8 98.8 97.9 95.0 相關物皙 已知外來之 類固醇總數 0.13-0.15 0.19 0.19 0.18 0.20 0.21 0.34 0.51 未知外來之 類固醇總數 0.03-0.04 0.19 0.24 0.26 0.36 0.43 0.68 1.8 0以不同日數完成分析,且 咕可以自表7之結果得知已曝露至/5 _與y-輻射之試樣中之布 ^索于仏3里減少。觀察一些新的降解產物,尤其該經7^ _ :射:忒樣。此外’經召_與卜輻射之試樣之質量平衡不佳。 田曝路至/5 _或r _輻射時,該布德索耐德含量減少un /於明顯的化學降解,可以推論微灰化布德索耐德不能滿 思地絰/3 -輻射或r _輻射滅菌。
O:\55\55669-921222.DOC -26-
Claims (1)
1242436 H87丫18179號專利申請案 *中文申請專利範菌♦換本(94年3月)
.一種治療上可接受之糖皮質類固醇,其選自布德索耐德 (budesonide),羅飛波耐德(roflep〇nide) ’羅飛波耐德棕櫊 酸醋,莫米松(momethasone)糠酸酯,貝克羅米松 (beCl〇methasone)二丙酸酯,氟替卡松(fhiticas〇ne)丙酸 酯,根據美國藥典23/NF18,其為無菌’其中該糖皮質類 ' 固醇係在100至130它之溫度下呈粉末型式經熱處理予以— 滅菌,其係呈乾燥微細緻粒子之型式,該粒子之質量中 位直徑(MMD)低於10微米,且具有大於98 5重量%之純 度。 2.根據申請專利範圍第丨項之治療上可接受之糖皮質類固 醇,其係呈乾燥微細緻粒子之型式,該粒子之質量中位 直徑(MMD)低於5微米。 3·根據申請專利範圍第丨項之治療上可接受之糖皮質類固 醇’且具有大於99.2重量%之純度。 4. 一種無菌醫藥調配物,其包含治療上可接受之糖皮質類 固醇,其選自布德索耐德(budes〇nide),羅飛波耐德籲 (r〇fleP〇nide),羅飛波耐德棕櫚酸醋,莫米松㈣ 糠酉夂酉日貝克羅米松(beclomethasone)二丙酸酯,氟替卡 松(fluticasone)丙酸酯,根據美國藥,其在水溶 · 液中為無菌,其中該糖皮質類固醇係在100至130°C之溫 度下呈粉末型式經熱處理予以滅菌,其係呈乾燥微細緻 粒子之型式’該粒子之質量中位直徑(MMD)低於1〇微 米’且具有大於98.5重量%之純度。 55669-940322.doc 1242436 5.根據申請專利範園钜音 IM _ 国弟4員之…、囷醫藥調配物,其中至少 8 0 /〇该糖皮質類固隨本 暂 只U醉粒子之貝里中位直徑(MMD)低於10 微米。 6·根據申請專利範圍第5項之無菌醫藥調配物,其中至少 〇/〇 口亥糖皮貝卖員固醇粒子之質量中位直徑(mmd)低於4微 米。 7·根據申請專利範圍第4、5或6項之無菌醫藥調配物,其進 步包含一或多種醫藥上可接受之添加物,稀釋劑或載 劑。 8.根據申請專利範圍第4、5或6項之無菌醫藥調配物,其包 含至少一個選自表面活化劑,ρΗ調整劑,螯合劑,懸浮 液等滲劑及增稠劑之添加物。 9·根據申叫專利範圍第4、5或6項之無菌醫藥調配物,其包 含0.05至20毫克/毫升該糖皮質類固醇。 ίο.根據申請專利範圍第9項之無菌醫藥調配物,其包含〇1 至5毫克/毫升該糖皮質類固醇。 11 ·根據申請專利範圍第4、5或6項之無菌醫藥調配物,其中 禮糖皮質類固醇為抗發炎糖皮質類固醇。 12·根據申請專利範圍第4、5或6項之無菌醫藥調配物,其中 口玄糖皮貝類固醇為布德索耐德(budesonjde)。 13· —種使糖皮質類固醇滅菌之方法,該糖皮質類固醇係選 自布德索耐德(budesonide),羅飛波耐德(rofleponide),及 貝克羅米松(beclomethasone)二丙酸酯,此方法包括於1〇〇 至130°C溫度下,使該呈粉末型式之糖皮質類固醇經熱處 55669-940322.doc 1242436 理’其中該糖皮質類固醇係呈乾燥微細緻粒子之型式, 該粒子之質量中位直徑(MMD)低於1Q微米,且具有大於 98.5重量%之純度。 根據申請專利範圍第13項之方法,其中該糖皮質類固醇 為抗發炎糠皮質類固醇。 15. 根據申請專利範圍第13或14項之方法,其中該糖皮質類 固醇為布德索耐德(budesonide)。 16. 根據申請專利範圍第13或14項之方法,其中該糖皮質類 固醇係於110至12〇乞溫度下經熱處理。 17. 根據中請專利範圍第13或14項之方法,其中該糖皮質類 固醇經熱處理費時不超過10小時。 18·根據申請專利範圍第13或14項之方法,纟中該糖皮質類 口醇係於110至13 0 c溫度下,經熱處理不超過8小時。 19·根據申請專利範圍第18項之方法,其中該糖皮質類固醇 係於110至130。(:溫度下,經熱處理不超過4小時。 2〇·根據申清專利範圍第〗8項之方法,其中該糖皮質類固醇 係於120°c溫度下,經熱處理不超過4小時。 21·根據申請專利範圍第2〇項之方法,其中該糖皮質類固醇 係於12〇°C溫度下,經熱處理不超過2小時。 22·根據申請專利範圍第⑴戈⑷員之方法,纟中該糖皮質類 固醇在經熱處理前,含有低於1% (w/w)水。 3 ·根據申凊專利範圍第22項之方法,其中該糖皮質類固醇 在經熱處理前,含有低於0.5% (w/w)水。 24.根據申請專利範圍第"或⑷員之方法,纟中該糖皮質類 55669-940322.doc 1242436 25 26. 27. 28. 固醇粉末之質量中位直徑(mmd) 孢子之數量減少超過6對數。 … < 在於抗熱 根據申清專利範圍第2 $首古_ “ ㈤弟25項之方法,其特徵在於抗熱孢子 <數量減少超過7對數。 =申請專利範圍第13或14項之方法,其特徵在於在預 定溫度T下,該D值低於240分鐘,其中丁在1〇〇至13〇它範 圍内。 根據申請專利範圍第27項之方法,其特徵在於在預定溫 度T下’該D值低於90分鐘,其中T在100至13 0°C範圍内。 55669-940322.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9704186A SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | New composition of matter |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI242436B true TWI242436B (en) | 2005-11-01 |
Family
ID=20408992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087118179A TWI242436B (en) | 1997-11-14 | 1998-11-02 | Therapeutically acceptable glucocorticosteroid in the form of a powder which is steriole according to the us pharmacopoeia 23/NF18, sterile pharmaceutical formulation comprising the same, and process for the sterilization of a glucocorticosteroid |
Country Status (24)
Country | Link |
---|---|
US (3) | US6392036B1 (zh) |
EP (1) | EP1032396B1 (zh) |
JP (2) | JP4598268B2 (zh) |
KR (1) | KR100571075B1 (zh) |
CN (1) | CN1173702C (zh) |
AR (1) | AR013765A1 (zh) |
AT (1) | ATE259642T1 (zh) |
AU (1) | AU744992B2 (zh) |
BR (1) | BR9814118A (zh) |
CA (1) | CA2310222C (zh) |
DE (1) | DE69821796T2 (zh) |
DK (1) | DK1032396T3 (zh) |
ES (1) | ES2214749T3 (zh) |
HK (1) | HK1030549A1 (zh) |
IL (1) | IL136086A (zh) |
MY (1) | MY118856A (zh) |
NO (1) | NO327391B1 (zh) |
NZ (1) | NZ504273A (zh) |
PT (1) | PT1032396E (zh) |
SA (1) | SA99190966B1 (zh) |
SE (1) | SE9704186D0 (zh) |
TW (1) | TWI242436B (zh) |
WO (1) | WO1999025359A1 (zh) |
ZA (1) | ZA9810217B (zh) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69633222T2 (de) * | 1995-02-24 | 2005-09-08 | Elan Pharma International Ltd. | Nanopartikel-dispersionen enthaltende aerosole |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
IT1303692B1 (it) | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
AR026072A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
AR026073A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
DK1337279T3 (da) | 2000-11-24 | 2006-09-25 | Breath Ltd | Sterilisation af glucocorticosteroidsuspensioner |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
GB0130055D0 (en) * | 2001-12-14 | 2002-02-06 | Technology Innovation Ltd | Medicament packaging |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
DK1471887T3 (da) * | 2002-02-04 | 2010-06-07 | Elan Pharma Int Ltd | Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel |
ATE418347T1 (de) | 2002-02-19 | 2009-01-15 | Resolution Chemicals Ltd | Auf lösungsmitteln basierende sterilisation von steroiden |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
KR101020687B1 (ko) * | 2002-07-02 | 2011-03-11 | 니코메드 게엠베하 | 사이클레소나이드 함유 멸균 수성 현탁액 |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
WO2004032980A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
EP1572217B1 (en) | 2002-12-12 | 2008-08-20 | Nycomed GmbH | Combination medicament of r,r-formoterol and ciclesonide |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
EP1454636A1 (en) * | 2003-03-04 | 2004-09-08 | Dompé S.P.A. | Sterilization of glucocorticoid drug particles for pulmonary delivery |
DE602004028585D1 (de) * | 2003-03-15 | 2010-09-23 | Brin Tech Internat Ltd | Verpackung für Arzneimittel |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
JP2007501683A (ja) * | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | γ線照射によるナノ粒子活性物質分散体の滅菌法 |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
GB0319500D0 (en) | 2003-08-19 | 2003-09-17 | Resolution Chemicals Ltd | Particle-size reduction apparatus,and use thereof |
PT1670482E (pt) | 2003-09-16 | 2014-03-12 | Takeda Gmbh | Utilização de ciclesonida para o tratamento de doenças respiratórias |
PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
WO2005088655A1 (en) * | 2004-03-12 | 2005-09-22 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A magnetoresistive medium |
ATE497787T1 (de) * | 2004-03-12 | 2011-02-15 | Cipla Ltd | Sterilisationsprozess für steroide |
WO2005102354A1 (en) * | 2004-04-20 | 2005-11-03 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
ITMI20040795A1 (it) * | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
GB0410995D0 (en) | 2004-05-17 | 2004-06-23 | Norton Healthcare Ltd | Heat sterilization of glucocorticosteroids |
ITSA20040012A1 (it) * | 2004-09-07 | 2004-12-07 | Genetec S P A | Processo di sterilizzazione di un glucocorticosteroide. |
GB0425266D0 (en) * | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
GB0427568D0 (en) | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
EP1782839A1 (en) | 2005-11-03 | 2007-05-09 | Genetic S.p.A. | Sterilization process of Glucocorticosteroid by supercritical CO2 |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20090252801A1 (en) * | 2005-11-29 | 2009-10-08 | Farmbios S.P.A. | Process for the Preparation of Micronised Sterile Steroids |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070166184A1 (en) * | 2006-01-13 | 2007-07-19 | Zimmer Technology, Inc. | Methods for cleaning and sterilizing devices |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
CA2642579A1 (en) * | 2006-02-15 | 2007-08-23 | Tika Lakemedel Ab | Sterilization of corticosteroids with reduced mass loss |
FR2898273B1 (fr) * | 2006-03-07 | 2013-11-08 | Merck Generiques | Procede de sterilisation par chauffage par voie seche d'une poudre comprenant un glucocorticosteroide |
MX2009000760A (es) * | 2006-07-20 | 2009-02-05 | Sicor Inc | Proceso para la preparacion de ingrediente farmaceutico activo esteril solido. |
CN102226026B (zh) * | 2007-03-12 | 2013-12-18 | 广东炜林纳功能材料有限公司 | 一种聚丙烯的复合β晶型成核剂 |
CN101265342B (zh) * | 2007-03-12 | 2014-04-02 | 广东炜林纳功能材料有限公司 | 一种聚丙烯的复合β晶型成核剂 |
MX2010005100A (es) * | 2007-11-09 | 2010-11-12 | Map Pharmaceuticals Inc | Metodos para administrar formulaciones de corticoesteroides. |
US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
JP2011503073A (ja) * | 2007-11-13 | 2011-01-27 | メリテイジ ファーマ,インク. | コルチコステロイド組成物 |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
KR20130097813A (ko) * | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
KR101534422B1 (ko) | 2008-05-14 | 2015-07-09 | 오토노미, 인코포레이티드 | 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 |
US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
CN102099013A (zh) * | 2008-07-14 | 2011-06-15 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放凋亡调节组合物和方法 |
US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
US8496957B2 (en) * | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
US8399018B2 (en) * | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
AU2009274229B2 (en) * | 2008-07-21 | 2013-08-22 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
EP2344151A4 (en) | 2008-10-22 | 2012-04-18 | House Ear Inst | THERAPEUTIC AND / OR PROPHYLACTIC TREATMENT OF INTERNAL EAR PATHOLOGIES BY MODULATION OF THE METABOTROPIC GLUTAMATE RECEPTOR |
KR20100079830A (ko) * | 2008-12-31 | 2010-07-08 | 삼성정밀화학 주식회사 | 입도 분포가 좁은 토너의 제조방법 |
LT3964502T (lt) | 2009-03-19 | 2024-08-26 | The Johns Hopkins University | Junginiai nukreipti į psma ir jų panaudojimas |
US20180009767A9 (en) | 2009-03-19 | 2018-01-11 | The Johns Hopkins University | Psma targeted fluorescent agents for image guided surgery |
US8273725B2 (en) | 2009-09-10 | 2012-09-25 | Genzyme Corporation | Stable hyaluronan/steroid formulation |
WO2011135585A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Aqueous pharmaceutical solution of ciclesonide |
ME02586B (me) | 2011-05-03 | 2017-06-20 | Chiesi Farm Spa | Unapređena suspendovana formulacija beklometazon dipropionata za administraciju putem inhalacije |
CA2909303C (en) * | 2013-03-15 | 2021-10-19 | Tracy RICHEY | Sustained release microspheres and method of producing the same |
CN105682742A (zh) | 2013-08-27 | 2016-06-15 | 奥德纳米有限公司 | 小儿耳部病症的治疗 |
WO2016042313A1 (en) * | 2014-09-15 | 2016-03-24 | Verona Pharma Plc | Liquid inhalation formulation comprising rpl554 |
EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA |
WO2018232280A1 (en) | 2017-06-15 | 2018-12-20 | The Johns Hopkins University | Psma targeted fluorescent agents for image guided surgery |
EP3668505A4 (en) | 2017-08-15 | 2021-05-12 | Nephron Pharmaceuticals Corporation | Aqueous fogging composition |
CN107510687B (zh) * | 2017-08-18 | 2020-07-03 | 南京海纳医药科技股份有限公司 | 一种供雾化用含有福莫特罗和布地奈德的吸入混悬液及其制备方法 |
CN108175763B (zh) * | 2017-12-19 | 2020-09-11 | 亿腾医药(苏州)有限公司 | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 |
GB202202297D0 (en) * | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US396430A (en) * | 1889-01-22 | Helm reichel | ||
US3337400A (en) * | 1965-10-08 | 1967-08-22 | Joel P Smith | Aqueous post-surgical injection by infiltration with a local anesthetic, a substantially water-insoluble, local anti-inflammatory gluco corticoid, and an antibiotic |
US3692430A (en) * | 1971-06-18 | 1972-09-19 | John W Timmons | Liquid pumping system |
US3992534A (en) * | 1972-05-19 | 1976-11-16 | Ab Bofors | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods |
US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
DE2837115A1 (de) * | 1978-08-25 | 1980-03-06 | Bayer Ag | Neues verfahren zur herstellung von sterilen feststoffen |
PT69652A (fr) | 1979-05-22 | 1979-06-01 | Quatrum Empresa Nacional De Qu | Procede pour la sterilization de produits non stables a hautes temperatures nommement steroides sous la forme de poudre contenus dans une emballage fermee |
JPS5732212A (en) | 1980-08-07 | 1982-02-20 | Mitsui Toatsu Chem Inc | Sterilizing method of acetylsalicylate salt |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
JPH0660106B2 (ja) | 1985-11-14 | 1994-08-10 | 徳男 斎藤 | 生薬類を主剤とする滅菌丸剤の製造法 |
US5407926A (en) * | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5380645A (en) * | 1989-03-16 | 1995-01-10 | The Johns Hopkins University | Generalized method for assessment of colorectal carcinoma |
SE8903219D0 (sv) * | 1989-10-02 | 1989-10-02 | Astra Ab | Process for the manufacture of budesonide |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
PL164294B1 (pl) | 1990-12-20 | 1994-07-29 | Inst Farmaceutyczny | Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL |
SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5491062A (en) * | 1993-11-23 | 1996-02-13 | Stratagene | Polynucleotide amplification mycoplasma assay, primers, and kits therefore |
US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
US5843644A (en) * | 1994-03-01 | 1998-12-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe |
GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
US5580728A (en) * | 1994-06-17 | 1996-12-03 | Perlin; Mark W. | Method and system for genotyping |
JPH10506280A (ja) * | 1994-09-23 | 1998-06-23 | ディー. フィンケルスタイン,シドニー | 形態的遺伝子型識別法 |
AU701440B2 (en) | 1994-09-29 | 1999-01-28 | Quadrant Drug Delivery Limited | Spray-dried microparticles as therapeutic vehicles |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5700794A (en) * | 1994-10-13 | 1997-12-23 | Alcon Laboratories Inc. | Treatment of ocular hypotony |
US6255483B1 (en) * | 1995-03-15 | 2001-07-03 | Ciba Specialty Chemicals Corporation | Biphenyl-substituted triazines |
SE9501384D0 (sv) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
AU6290396A (en) * | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
JPH0930988A (ja) * | 1995-07-21 | 1997-02-04 | Sumitomo Osaka Cement Co Ltd | 薬剤徐放性多孔質セラミックス成形体及びその製造方法 |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
US5792758A (en) * | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
SE9604486D0 (sv) * | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
DE29717252U1 (de) * | 1997-09-26 | 1998-02-19 | Dr. Falk Pharma GmbH, 79108 Freiburg | Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen |
US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
CA2305256C (en) | 1997-10-09 | 2005-05-17 | Schering Corporation | Mometasone furoate suspensions for nebulization |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
US6066292A (en) * | 1997-12-19 | 2000-05-23 | Bayer Corporation | Sterilization process for pharmaceutical suspensions |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
DK1337279T3 (da) * | 2000-11-24 | 2006-09-25 | Breath Ltd | Sterilisation af glucocorticosteroidsuspensioner |
ATE418347T1 (de) | 2002-02-19 | 2009-01-15 | Resolution Chemicals Ltd | Auf lösungsmitteln basierende sterilisation von steroiden |
ITMI20022674A1 (it) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
ITMI20032054A1 (it) * | 2003-10-22 | 2005-04-23 | Monteres S R L | Processo per la preparazione di sospensioni farmaceutiche da inalare. |
ATE497787T1 (de) * | 2004-03-12 | 2011-02-15 | Cipla Ltd | Sterilisationsprozess für steroide |
-
1997
- 1997-11-14 SE SE9704186A patent/SE9704186D0/xx unknown
-
1998
- 1998-11-02 TW TW087118179A patent/TWI242436B/zh not_active IP Right Cessation
- 1998-11-09 ZA ZA9810217A patent/ZA9810217B/xx unknown
- 1998-11-10 MY MYPI98005104A patent/MY118856A/en unknown
- 1998-11-11 JP JP2000520792A patent/JP4598268B2/ja not_active Expired - Lifetime
- 1998-11-11 NZ NZ504273A patent/NZ504273A/en not_active IP Right Cessation
- 1998-11-11 US US09/230,781 patent/US6392036B1/en not_active Expired - Lifetime
- 1998-11-11 KR KR1020007005212A patent/KR100571075B1/ko not_active IP Right Cessation
- 1998-11-11 IL IL13608698A patent/IL136086A/xx not_active IP Right Cessation
- 1998-11-11 PT PT98956058T patent/PT1032396E/pt unknown
- 1998-11-11 AU AU12666/99A patent/AU744992B2/en not_active Expired
- 1998-11-11 CA CA002310222A patent/CA2310222C/en not_active Expired - Lifetime
- 1998-11-11 DK DK98956058T patent/DK1032396T3/da active
- 1998-11-11 CN CNB988131099A patent/CN1173702C/zh not_active Expired - Lifetime
- 1998-11-11 BR BR9814118-0A patent/BR9814118A/pt not_active Application Discontinuation
- 1998-11-11 ES ES98956058T patent/ES2214749T3/es not_active Expired - Lifetime
- 1998-11-11 DE DE1998621796 patent/DE69821796T2/de not_active Expired - Lifetime
- 1998-11-11 AT AT98956058T patent/ATE259642T1/de active
- 1998-11-11 EP EP98956058A patent/EP1032396B1/en not_active Expired - Lifetime
- 1998-11-11 WO PCT/SE1998/002039 patent/WO1999025359A1/en active IP Right Grant
- 1998-11-13 AR ARP980105761A patent/AR013765A1/es active IP Right Grant
-
1999
- 1999-01-05 SA SA99190966A patent/SA99190966B1/ar unknown
-
2000
- 2000-05-12 NO NO20002470A patent/NO327391B1/no not_active IP Right Cessation
-
2001
- 2001-03-02 HK HK01101540A patent/HK1030549A1/xx not_active IP Right Cessation
- 2001-11-27 US US09/993,669 patent/US7524834B2/en not_active Expired - Fee Related
-
2007
- 2007-03-23 US US11/690,537 patent/US20070197489A1/en not_active Abandoned
-
2009
- 2009-12-25 JP JP2009293641A patent/JP2010070567A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI242436B (en) | Therapeutically acceptable glucocorticosteroid in the form of a powder which is steriole according to the us pharmacopoeia 23/NF18, sterile pharmaceutical formulation comprising the same, and process for the sterilization of a glucocorticosteroid | |
EP1126823B1 (en) | A process for the preparation of sterile therapeutically acceptable beclomethasone dipropionate | |
AU2004298447B2 (en) | Aqueous suspensions of ciclesonide for nebulisation | |
AU2005247422B2 (en) | Heat sterilization of glucocorticosteroids | |
JP2022062172A (ja) | 無菌眼用水性プロピオン酸フルチカゾンa型ナノ結晶懸濁液の調製方法 | |
JP4712689B2 (ja) | 肺送達用ベクロメタゾン薬粒子の滅菌 | |
MXPA00004648A (en) | New composition of matter | |
TR2023013885T2 (tr) | Nebuli̇zasyon yoluyla i̇nhalasyon i̇çi̇n steri̇li̇ze edi̇lmi̇ş süspansi̇yonlarin hazirlanmasi yöntemi̇ | |
WO2022098321A1 (en) | Process for the preparation of sterilised suspensions for the administration by inhalation | |
WO2022231531A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
MXPA06006537A (en) | Aqueous suspensions of ciclesonide for nebulisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |